Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

This phase 1b/2a multicenter, open-label trial evaluated Descartes-08, an autologous RNA-engineered anti-BCMA CAR T-cell therapy, in 14 adults with generalized myasthenia gravis (MG). Unlike conventional DNA-based CAR T therapies, Descartes-08 utilizes transient mRNA expression, eliminating the need for lymphodepletion. Participants received up to six weekly infusions. The therapy was well